| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
ORIGINAL ARTICLES |
From the Department of Surgical Oncology (NEJ, ERS) and Division of Population Science and the Department of Biostatistics (ALH, HW), Fox Chase Cancer Center, Philadelphia, Pennsylvania; Cancer and Leukemia Group B (RJM), Boston, Massachusetts; Southwest Oncology Group (JSM), Philadelphia, Pennsylvania; Dana-Farber Cancer Institute (PJC), Boston, Massachusetts; and Eastern Cooperative Oncology Group (DGH), Philadelphia, Pennsylvania.
Correspondence: Address correspondence and reprint requests to: Elin R. Sigurdson, MD, PhD, Department of Surgical Oncology, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, PA 19111; Fax: 215-728-2773; E-mail: e_sigurdson{at}fccc.edu
Background: Correct determination of nodal status is pivotal to accurate staging and predicting survival.
Methods: This is a secondary analysis of INT0089, an intergroup trial of adjuvant chemotherapy for high-risk stage II and III colon cancer. A subset of patients was studied who underwent right or left hemicolectomy and from whom at least 10 lymph nodes were examined. A mathematical model was created to estimate the probability of a true negative result on the basis of the number of nodes examined. The number of nodes needed to predict nodal negativity with 85%, 50%, and 25% probability on the basis of tumor stage was calculated.
Results: In this analysis, 1585 patients were studied. The average number of nodes removed at surgery was comparable between treatment groups at 18.5 (median of 16 in all groups). With this model, when 18 nodes are removed at resection, there is a <25% probability of true node negativity in T1/T2 tumors, whereas <10 nodes need to be examined in T3 and T4 tumors to achieve the same probability.
Conclusions: Tumor stage and the number of nodes retrieved at resection influence the accuracy of determining nodal status in colon cancer. Most patients are understaged. Underestimating nodal stage may influence decisions regarding adjuvant therapy, as well as overall prognosis.
Key Words: Lymph node status • Colon cancer • Survival • 5-fluorouracil chemotherapy • Prognostic factors
This article has been cited by other articles:
 |
|
 |
|
  R. A. Cahill, S. Perretta, J. Leroy, B. Dallemagne, and J. Marescaux Lymphatic Mapping and Sentinel Node Biopsy in the Colonic Mesentery by Natural Orifice Transluminal Endoscopic Surgery (NOTES) Ann. Surg. Oncol., October 1, 2008; 15(10): 2677 - 2683. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Y. Bilimoria, D. J. Bentrem, A. K. Stewart, M. S. Talamonti, D. P. Winchester, T. R. Russell, and C. Y. Ko Lymph Node Evaluation as a Colon Cancer Quality Measure: A National Hospital Report Card J Natl Cancer Inst, September 17, 2008; 100(18): 1310 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Hill, W. L. Furman, C. A. Billups, S. E. Riedley, A. M. Cain, B. N. Rao, C. B. Pratt, and S. L. Spunt Colorectal Carcinoma in Childhood and Adolescence: A Clinicopathologic Review J. Clin. Oncol., December 20, 2007; 25(36): 5808 - 5814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Compton Optimal Pathologic Staging: Defining Stage II Disease Clin. Cancer Res., November 15, 2007; 13(22): 6862s - 6870s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Chen and A. J. Bilchik Resecting Lymph Nodes in Colon Cancer: More than a Staging Operation? Ann. Surg. Oncol., August 1, 2007; 14(8): 2175 - 2176. [Full Text] [PDF]
|
|
|
|
|
|
E. J. A. Morris, N. J. Maughan, D. Forman, and P. Quirke Identifying Stage III Colorectal Cancer Patients: The Influence of the Patient, Surgeon, and Pathologist J. Clin. Oncol., June 20, 2007; 25(18): 2573 - 2579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Lee, H.-J. Choi, K.-J. Park, J.-S. Shin, H.-C. Kwon, M.-S. Roh, and C. Kim Prognostic Significance of Metastatic Lymph Node Ratio in Node-Positive Colon Carcinoma Ann. Surg. Oncol., May 1, 2007; 14(5): 1712 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Johnson, G. A. Porter, R. Ricciardi, and N. N. Baxter Increasing Negative Lymph Node Count Is Independently Associated With Improved Long-Term Survival in Stage IIIB and IIIC Colon Cancer J. Clin. Oncol., August 1, 2006; 24(22): 3570 - 3575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Bilchik, M. DiNome, S. Saha, R. R. Turner, D. Wiese, M. McCarter, D. S. B. Hoon, and D. L. Morton Prospective Multicenter Trial of Staging Adequacy in Colon Cancer: Preliminary Results Arch Surg, June 1, 2006; 141(6): 527 - 534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Haller, P. J. Catalano, J. S. Macdonald, M. A. O'Rourke, M. S. Frontiera, D. V. Jackson, and R. J. Mayer Phase III Study of Fluorouracil, Leucovorin, and Levamisole in High-Risk Stage II and III Colon Cancer: Final Report of Intergroup 0089 J. Clin. Oncol., December 1, 2005; 23(34): 8671 - 8678. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Berger, E. R. Sigurdson, T. LeVoyer, A. Hanlon, R. J. Mayer, J. S. Macdonald, P. J. Catalano, and D. G. Haller Colon Cancer Survival Is Associated With Decreasing Ratio of Metastatic to Examined Lymph Nodes J. Clin. Oncol., December 1, 2005; 23(34): 8706 - 8712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Wong, D. S. Johnson, D. Hemmings, A. Hsu, T. Imai, and G. T. Tominaga Assessing the Quality of Colorectal Cancer Staging: Documenting the Process in Improving the Staging of Node-Negative Colorectal Cancer Arch Surg, September 1, 2005; 140(9): 881 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Ray-Coquard, T. Philip, G. de Laroche, X. Froger, J.-P. Suchaud, A. Voloch, H. Mathieu-Daude, A. Lurkin, F. Farsi, P. Bertrand, et al. Persistence of Medical Change at Implementation of Clinical Guidelines on Medical Practice: A Controlled Study in a Cancer Network J. Clin. Oncol., July 1, 2005; 23(19): 4414 - 4423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. N. Baxter, D. J. Virnig, D. A. Rothenberger, A. M. Morris, J. Jessurun, and B. A. Virnig Lymph Node Evaluation in Colorectal Cancer Patients: A Population-Based Study J Natl Cancer Inst, February 2, 2005; 97(3): 219 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Compton and F. L. Greene The Staging of Colorectal Cancer: 2004 and Beyond CA Cancer J Clin, November 1, 2004; 54(6): 295 - 308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N P Zauber, C Wang, P S Lee, T C Redondo, D T Bishop, and A Goel Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival J. Clin. Pathol., September 1, 2004; 57(9): 938 - 942. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. E. Enker Editorial: The Elusive Goal of Preoperative Staging in Rectal Cancer Ann. Surg. Oncol., March 1, 2004; 11(3): 245 - 246. [Full Text] [PDF]
|
|
|
|
|
|
A. Bilchik More (Nodes) + More (Analysis) = Less (Mortality): Challenging the Therapeutic Equation for Early-Stage Colon Cancer Ann. Surg. Oncol., April 1, 2003; 10(3): 203 - 205. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
